TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05162729

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game-like online working memory training
Description: Participants in the WM group will be receiving two types of WM training tasks (two mini-games) in each session. Half of the training time will be spent on playing a game that requires visual-spatial WM, and the other half of the training time will be spent on playing a game that demands verbal WM. In both the games, the participant is asked to remember the pictures or audios (numbers) presented, and then recall them and select them on the screen.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Game-like online social emotional training
Description: Participants in the SE group will be also receiving two types of SE training tasks in each session, to match with the ones in the WM training. There are two mini-games for training.~To match with the spatial-visual WM training, participants in the SE group will be asked to first look at a picture that depicts a daily social scenario (i.e., a child who fell down and hurt himself), and then to choose an emotion that the child in the picture may feel from four options of facial emotions displayed on the screen. The other mini-game, with the aim to match with the auditory WM training, will first tell a short story of a social scenario (i.e. David accidentally fell down and got hurt), and then will ask the child to choose the emotion that the character in the story may feel from the four options displayed on the screen. Each mini game lasts for about 7 minutes in each training session.
Study: NCT05730712

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronidase-zzxf/Pertuzumab/Trastuzumab
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05082324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted physical activity
Description: Patient participates in an adapted physical activity program for 3 months, with 2 one-hour sports sessions per week
Study: NCT05664217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-255 at 1.5 µg/kg
Description: NKTR-255 at 1.5 µg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-255 at 3.0 μg/kg
Description: NKTR-255 at 3.0 μg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-255 at 3.0/6.0 μg/kg
Description: NKTR-255 at 3.0/6.0 μg/kg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Commercially available 0.9% Sodium Chloride Solution for Injection (USP)
Study: NCT05647044

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo intermittent theta burst stimulation
Description: intermittent theta burst stimulation (iTBS) will be delivered with the Magventure MagProX100 with MagOption stimulation and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo. The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
Study: NCT05233449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NoL monitor
Description: NoL monitor : non invasive, adhesive digital device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stimulation
Description: Stimulation : 100 Hertz, 5 seconds, 10-30-60 milliamps, inner forearm
Study: NCT04729582

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Primary human muscle stem cells (Satori-01)
Description: Primary human muscle stem cells are isolated from patient's muscle tissue and expanded ex-vivo. They are injected into the urethral sphincter region as a one-time autologous treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is the injection solution without muscle stem cells.
Study: NCT04937816

Intervention type: DRUG
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Intervention: Empagliflozin
Description: Empagliflozin once daily

Intervention type: DRUG
Intervention: Empagliflozin
Description: Empagliflozin once daily

Intervention type: DRUG
Intervention: Empagliflozin
Description: Empagliflozin once daily
Study: NCT06203834

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: I-Fiber Pearl
Description: Eat 200g for once, and once a day.
Study: NCT05987072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sisunatovir
Description: Will be given as a single dose on Day 1 in a fasted state followed by repeated twice daily doses (200 mg BID, Q12 hours) from Days 4-7 plus 1 morning dose on Day 8 in a fed state
Study: NCT04937816

Intervention type: DRUG
Intervention: Empagliflozin
Description: Empagliflozin once daily
Study: NCT05339243

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ES 1
Description: Two capsules orally once daily after breakfast for 84 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HT ES1
Description: Two capsules orally once daily after breakfast for 84 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules orally once daily after breakfast for 84 days
Study: NCT06203834

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Eat 200g for once, and once a day.
Study: NCT06323915

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intraocular lens implantation in cataract surgery
Description: Implantation of intra ocular lenses in both patient's eyes in remplacement of the natural cataracted cristallin that has been removed from the patient's eye during the cataract surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intraocular lens implantation in cataract surgery
Description: Implantation of intra ocular lenses in both patient's eyes in remplacement of the natural cataracted cristallin that has been removed from the patient's eye during the cataract surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intraocular lens implantation in cataract surgery
Description: Implantation of intra ocular lenses in both patient's eyes in remplacement of the natural cataracted cristallin that has been removed from the patient's eye during the cataract surgery
Study: NCT06291116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard care + rotigotine at 4 mg/24h for 24 months.
Description: standard care + rotigotine at 4 mg/24h for 24 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard care for 24 months.
Description: standard care for 24 months.
Study: NCT06312943

Intervention type: OTHER
Intervention: Collection of joint fluid or tissue sample
Description: During a puncture or joint surgery planned as part of the routine care of the patient, a part of the joint fluid or tissue sample will be collected in order to carry out the analyzes planned for the research.
Study: NCT05717114

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Pecs block
Description: (Pecs block):the block will be performed with the patients in the supine position.The infraclavicular and axillary regions will be cleaned with antiseptic solution. the inplane technique will be used from proximal and medial to distal and lateral in an oblique manner at dermatome level T2and T3.The puncture site was infiltrated with 2%lidocaine and once the structures is identified with ultrasound.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pecs block
Description: (Pecs block):the block will be performed with the patients in the supine position.The infraclavicular and axillary regions will be cleaned with antiseptic solution. the inplane technique will be used from proximal and medial to distal and lateral in an oblique manner at dermatome level T2and T3.The puncture site was infiltrated with 2%lidocaine and once the structures is identified with ultrasound.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pecs block
Description: (Pecs block):the block will be performed with the patients in the supine position.The infraclavicular and axillary regions will be cleaned with antiseptic solution. the inplane technique will be used from proximal and medial to distal and lateral in an oblique manner at dermatome level T2and T3.The puncture site was infiltrated with 2%lidocaine and once the structures is identified with ultrasound.
Study: NCT06086080

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Bracing and physical therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Bracing and physical therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taping
Description: The patient is treated with tape in special configuration (McConell modified) for the patella + standard care

Intervention type: DEVICE
Group type: OTHER
Intervention: Sham taping
Description: Taping with no treatment disposition
Study: NCT05323838

Intervention type: BEHAVIORAL
Intervention: Subjective quality of live
Description: The groups fill out scientifically validated questionnaires to know the differences in perceived stress, anxiety, quality of life, depression, quality of sleep, pain, fatigue, and impact of the disease on daily life.

Intervention type: BEHAVIORAL
Intervention: Subjective quality of live
Description: The groups fill out scientifically validated questionnaires to know the differences in perceived stress, anxiety, quality of life, depression, quality of sleep, pain, fatigue, and impact of the disease on daily life.

Intervention type: BEHAVIORAL
Intervention: Subjective quality of live
Description: The groups fill out scientifically validated questionnaires to know the differences in perceived stress, anxiety, quality of life, depression, quality of sleep, pain, fatigue, and impact of the disease on daily life.

Intervention type: PROCEDURE
Intervention: Blood extraction
Description: Blood collection by qualified personnel.

Intervention type: PROCEDURE
Intervention: Blood extraction
Description: Blood collection by qualified personnel.

Intervention type: PROCEDURE
Intervention: Blood extraction
Description: Blood collection by qualified personnel.

Intervention type: BEHAVIORAL
Intervention: Accelerometry
Description: To know the objective differences between physical activity/sedentary lifestyle, caloric expenditure and quality of sleep, we used the accelerometry technique

Intervention type: BEHAVIORAL
Intervention: Accelerometry
Description: To know the objective differences between physical activity/sedentary lifestyle, caloric expenditure and quality of sleep, we used the accelerometry technique

Intervention type: BEHAVIORAL
Intervention: Accelerometry
Description: To know the objective differences between physical activity/sedentary lifestyle, caloric expenditure and quality of sleep, we used the accelerometry technique

Intervention type: DIETARY_SUPPLEMENT
Intervention: Synbiotic complement
Description: On two separate days, the baseline-tests and final-tests were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the final-test and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (synbiotic).

Intervention type: DIETARY_SUPPLEMENT
Intervention: Synbiotic complement
Description: On two separate days, the baseline-tests and final-tests were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the final-test and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (synbiotic).
Study: NCT05093712

Intervention type: OTHER
Intervention: Educational Intervention
Description: Watch educational video

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete surveys

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete surveys
Study: NCT06028451

Intervention type: OTHER
Intervention: Record the information data
Description: Record the information data

Intervention type: OTHER
Intervention: Record the information data
Description: Record the information data
Study: NCT06372912

Intervention type: PROCEDURE
Intervention: Sleeve gastrectomy, Roux-en-Y gastric bypass, mini-gastric bypass, SADIS, intragastric balloon insertion, and gastric band placement are bariatric surgeries.
Description: Sleeve gastrectomy: reduces stomach size. Roux-en-Y gastric bypass: limits calorie absorption. Mini gastric bypass: achieves weight loss with fewer incisions. SADIS: combines sleeve gastrectomy with small bowel bypass. Intragastric balloon: reduces stomach volume. Gastric banding: restricts food intake.
Study: NCT05620303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Parents/guardians will receive three different contents weekly (i.e., infographics, video recipes, information pills, or videos) each week related to 24-h movement behaviors (i.e., PA, sedentary behavior, sleep duration) or Mediterranean Diet for 36 weeks.
Study: NCT05883033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VAC
Description: Vacuum Assisted Closure device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VAC
Description: Vacuum Assisted Closure device
Study: NCT05470322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er: YAG laser
Description: Patients will be treated with laser for their HS scarring.
Study: NCT05403957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TID video
Description: Main intervention: A video introducing the tobacco industry's marketing tactics to attract children and adolescents to smoke and their manipulation of tobacco control policy formation.~Booster intervention: 6 screenshots from the video and 6 true or false questions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TID worksheet
Description: Main intervention: A worksheet using pictures and texts to introduce the tobacco industry's marketing tactics to attract children and adolescents to smoke and their manipulation of tobacco control policy formation.~Booster intervention: 8 pictures from the TID worksheet in the main intervention and 6 true or false questions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SSB worksheet
Description: Main intervention: A worksheet using pictures and texts to introduce the beverage industry's marketing tactics to attract children and adolescents to drink SSBs and the health risks of SSBs.~Booster intervention: 8 pictures from the SSB worksheet in the main intervention and 6 true or false questions.
Study: NCT06460272

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medically Tailored Meals
Description: Meals culturally tailored to provide essential nutrition

Intervention type: OTHER
Group type: OTHER
Intervention: Medically Tailored Meals
Description: Meals culturally tailored to provide essential nutrition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medically Tailored Meals
Description: Meals culturally tailored to provide essential nutrition
Study: NCT05002725

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocain
Description: 300mg (20ml) will be injected

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocain
Description: 300mg (20ml) will be injected
Study: NCT06537791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-Based Rehabilitation Program
Description: Physical Therapy: 32 sessions, 60 minutes each Occupational Therapy: 8 sessions, 60 minutes each Nutrition Counseling: 4 sessions, 60 minutes each Psychological Support: 8 sessions, 60 minutes each Nursing and Podiatry Care: 4 sessions, 60 minutes each Total Duration: Approximately 4 months
Study: NCT05790356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbial transplant
Description: Fecal microbial transplant will be investigated for its effect on gut bacterial composition in patients with rheumatoid arthritis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: The placebo capsules will not contain FMT but will have the same appearance.
Study: NCT04743973

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muse S™ Headband system
Description: Brain sensing headband that measures brain activity by detecting electrical impulses created by the brain.
Study: NCT06720350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab and Denosumab Combination Therapy
Description: Romosozumab 210mg per month and denosumab 60mg per 6 months will be applied

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Romosozumab Prefilled Syringe [Evenity]
Description: Romosozumab 210mg subcutaneously per month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab (Prolia)
Description: Denosumab 60 mg subcutaneously per 6 months
Study: NCT06719856

Intervention type: DRUG
Intervention: 18-FDG
Description: All study participants will undergo one 18F-FDG PET/ CT scan.
Study: NCT06707389

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous blood monocyte vesicles (lower dose)
Description: 20 ml peripheral venous blood was extracted from each patient, anticoagulated with heparin and diluted with PBS. Peripheral blood mononuclear cells were isolated by Ficoll stratified solution. Extracellular vesicles of mononuclear cells were extracted by gradient centrifugation (800g centrifugation at 4 ℃ for 10 minutes, then 2000g centrifugation at centrifuged at 4 ℃ for 10 minutes and then 16000g centrifugation at 4 ℃ for 30 minutes. The precipitate was taken as monocyte vesicle and stored in refrigerator at 4 ℃. For intratympanic injection, precipitate was dissolved in 0.2 ml of lidocaine and 0.8 ml of sterilized injection water. Intratympanic injection of apoVs was performed three times a week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: 40mg of methylprednisolone was dissolved in 0.2 ml of lidocaine injection and 0.8 ml of sterilized injection water. Intratympanic injection of methylprednisolone was performed three times a week.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous blood monocyte vesicles (higher dose)
Description: 50 ml peripheral venous blood was extracted from each patient, anticoagulated with heparin and diluted with PBS. Peripheral blood mononuclear cells were isolated by Ficoll stratified solution. Extracellular vesicles of mononuclear cells were extracted by gradient centrifugation (800g centrifugation at 4 ℃ for 10 minutes, then 2000g centrifugation at centrifuged at 4 ℃ for 10 minutes and then 16000g centrifugation at 4 ℃ for 30 minutes. The precipitate was taken as monocyte vesicle and stored in refrigerator at 4 ℃. For intratympanic injection, precipitate was dissolved in 0.2 ml of lidocaine and 0.8 ml of sterilized injection water. Intratympanic injection of apoVs was performed three times a week.
Study: NCT06716580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Circulating Tumor DNA (ctDNA) Assay
Description: Screening investigational blood test to test for EGFR L858R and exon 19 deletions, which comprise 85-90% of total EGFR mutations. A positive or indeterminate investigational test will be followed up by CLIA verification of results. A positive or indeterminate CLIA result will be followed up by a lung CT scan. A positive CT scan will be followed up by referral for further evaluation. A negative CT scan will be followed up by a repeat scan in 12 months.
Study: NCT06709534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participate in an individualized online home-based exercise intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Assessment
Description: Complete functional capacity assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear an activity tracker

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Receive social support
Study: NCT06732258

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy
Description: The LDRT deals with primary tumour in a 15 Gy of 5 fractions over five days, starting from Day 1 in the first cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tifcemalimab injection
Description: 100 mg or 200 mg q3w until disease progression or intolerable toxicity;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240 mg q3w until disease progression or intolerable toxicity;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 q3w for 4-6 cycles;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC = 5, q3w for 4-6 cycles;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m2, d1, d2, d3, q3w for 4-6 cycles;
Study: NCT06745232

Intervention type: DEVICE
Intervention: FAST MAP
Description: Patients with complete arch restorations loaded immediately with a full digital workflow using stereophotogrammetry Intraoral impression
Study: NCT06751056

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical Traction Device
Description: Participants will use their home neck traction devices daily for 12 weeks, while continuing their prescriptions for gabapentin or pregabalin.~At study initiation and every 2 weeks thereafter for a total of 12 weeks, they will receive an electronic survey assessing their itch score. Based on survey results, they will receive a call from the study team to adjust their dosage of gabapentin or pregabalin by up to 33%.
Study: NCT06749015

Intervention type: OTHER
Intervention: Non interventional study
Description: Non interventional study
Study: NCT06749028

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention Arm: Omega-3 + Phospholipids.
Description: Intervention Arm: Omega-3 + Phospholipids.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Comparator Arm: Omega-3 alone.
Description: Comparator Arm: Omega-3 alone.